Indications for OZEMPIC:
As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). To reduce the risk of major cardiovascular (CV) events (eg, CV death, non-fatal MI or non-fatal stroke) in adults with T2DM and established CV disease.
Limitations of Use:
Not studied with a history of pancreatitis. Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis.
Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Initially 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for at least 4 weeks; if additional control needed, may increase to 1mg once weekly (max).
<18yrs: not established.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors.
Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. Do not reuse or share pens or needles between patients. Monitor renal function when initiating or escalating dose. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Discontinue if hypersensitivity reactions occur. Pregnancy. Females of reproductive potential: discontinue ≥2 months prior to planned pregnancy. Nursing mothers.
Glucagon-like peptide-1 (GLP-1) receptor agonist.
Concomitant insulin; administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); caution.
Nausea, vomiting, diarrhea, abdominal pain, constipation; rare: pancreatitis, hypersensitivity reactions.
Single-patient-use pre-filled pen (0.25mg or 0.5mg per inj)—1; (1mg per inj)—2